Ciusss de L'Est de l'Île de Montréal
ciusss-estmtl.gouv.qc.caTotal trials
87
Active
30
Phase 3
2
Total enrollment
24,022
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 16 of 16 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Esmolol Hydrochloride | — | — | — | — | — | 1 | |
| Saline | — | — | — | — | — | 1 | |
| Transplant with an expanded ECT-001 cord blood | — | — | — | — | — | 1 | |
| Melatonin | — | — | — | — | — | 1 | |
| ECT-001-CB | — | — | — | — | — | 1 | |
| Modified early post-operative intraperitoneal chemotherapy | — | — | — | — | — | 1 | |
| Dexmedetomidine | — | — | — | — | — | 2 | |
| Programmed intermittent epidural bolus 5 ml | — | — | — | — | — | 1 | |
| Programmed intermittent epidural bolus 6 ml | — | — | — | — | — | 1 | |
| Programmed intermittent epidural bolus 7 ml | — | — | — | — | — | 1 | |
| Programmed intermittent epidural bolus 8 ml | — | — | — | — | — | 1 | |
| Programmed intermittent epidural bolus 9 ml | — | — | — | — | — | 1 | |
| Programmed intermittent epidural bolus 10 ml | — | — | — | — | — | 1 | |
| Ketamine Hydrochloride | — | — | — | — | — | 1 | |
| Dexmedetomidine Hydrochloride | — | — | — | — | — | 1 | |
| dexmedetomidine Hydrochloride and Ketamine Hydrochloride | — | — | — | — | — | 1 |
Next readouts
- 2025-03-03
- 2025-11
- 2025-12-01
- 2026-07
- 2026-12-30
- 2027-06
- 2027-10
- 2028-05
Top conditions
- Anesthesia14
- Nociceptive Pain4
- Chronic Pain3
- Auditory Hallucination, Verbal3
- Treatment-resistant Schizophrenia3
- Postoperative Pain3
- Hypnosis2
- Pain2
Frequently asked questions about Ciusss de L'Est de l'Île de Montréal
- How many clinical trials does Ciusss de L'Est de l'Île de Montréal have on ClinicalTrials.gov?
- Ciusss de L'Est de l'Île de Montréal is listed as the lead sponsor on 87 clinical trials in ClinicalTrials.gov, 30 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Ciusss de L'Est de l'Île de Montréal's trials are in Phase 3?
- 2 of Ciusss de L'Est de l'Île de Montréal's trials are in Phase 3, spread across 16 active drug programs.
- What therapeutic areas does Ciusss de L'Est de l'Île de Montréal focus on?
- Ciusss de L'Est de l'Île de Montréal's most-studied conditions on ClinicalTrials.gov are Anesthesia, Nociceptive Pain, Chronic Pain, Auditory Hallucination, Verbal, Treatment-resistant Schizophrenia.
- When are Ciusss de L'Est de l'Île de Montréal's next clinical trial readouts?
- Ciusss de L'Est de l'Île de Montréal has 8 upcoming primary-completion readouts tracked here; the soonest is “Impact of Administration of Esmolol on Nociception Level-guided Control of Nociception.”, expected around 2025-03-03.